SolasCure Completes Phase II Clinical Trial, Demonstrating Accelerated Healing With Aurase Wound Gel
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the successful completion of its second Phase II clinical trial, CLEANVLU2. The study demonstrated that its investigational product, Aurase Wound Gel (AWG), heals chronic wounds at a faster rate than current standard of care, providing clinical validation of its ability to deliver continuous enzymatic debridement while simultaneously activating wound healing.
SolasCure Enrols First Patient in a Next Phase II Clinical Trial to Advance Aurase Wound Gel
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of a new Phase II clinical trial, CLEANVLU2. The enrolment of the trial’s first patient marks a new clinical milestone in the development of its investigational product, Aurase Wound Gel, for the treatment of chronic wounds.
